Clinical Trials on KRAS Gene Mutation

Conditions: Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation, KRAS Gene Mutation, BRAF Gene Mutation

Conditions: KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

Conditions: Metastatic Colorectal Cancer, KRAS Gene Mutation

Conditions: Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation

Conditions: KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7

Conditions: BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8

Conditions: Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related, Molecular Sequence Variation, Genetic Alteration, Gene Fusion, Receptor Tyrosine Kinase Gene Mutation, RTK Family Gene Mutation, Ras (Kras or Nras) Gene Mutation

Conditions: Lung Cancer, Non-small Cell Lung Cancer, PD-L1 Gene Mutation, KRAS Activating Mutation

Conditions: KRAS Gene Mutation Advanced Non-small Cell Lung Cancer

Conditions: KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7

Conditions: Colorectal Cancer Metastatic, Circulating Tumor DNA, KRAS Gene Mutation, NRAS Gene Mutation, BRAF Gene Mutation, Epidermal Growth Factor Receptor Inhibitor

Conditions: KRAS Gene Mutation

Conditions: Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation

Conditions: Non Small Cell Lung Cancer, KRAS Gene Mutation

Conditions: Advanced Malignant Solid Neoplasm, KRAS Gene Mutation, Ovarian Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma

Conditions: Solid Tumors, NSCLC, CRC, KRAS Gene Mutation

Conditions: Colorectal Cancer, APC Gene Mutation, TP53 Gene Mutation, PIK3CA Gene Mutation, KRAS Mutation-Related Tumors, MLH1 Gene Mutation

Conditions: Advanced Non-small Cell Lung Cancer, KRAS Gene Mutation, Lung Cancer

Conditions: Infiltrating Urothelial Carcinoma, KRAS Gene Mutation

Conditions: NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer, CRPC, Pancreatic Ductal Adenocarcinoma

Conditions: Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm

Conditions: Metastatic Colorectal Cancer, KRAS Gene Mutation

Conditions: EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7

Conditions: Lung Neoplasms, KRAS Gene Mutation, EGFR Gene Mutation

Conditions: NSCLC Stage IV, KRAS Gene Mutation, PD-1 Antibody, Chemotherapy Effect